Beware of HCV and HEV in Patients with Suspected Drug-Induced Liver Injury.
Beware of HCV and HEV in Patients with Suspected Drug-Induced Liver Injury.
复制标题
DOI：
10.1007/s11901-018-0410-1
复制
发表时间：
2018-09-01
期刊：
影响因子：
--
通讯作者：
Ahmad, Jawad
中科院分区：
文献类型：
--
作者：
Grewal, Priya;Ahmad, Jawad
审查目的：在没有特异性生物标志物的情况下，药物性肝损伤（DILI）的诊断依赖于排除其他肝损伤原因。本综述探讨了丙型肝炎（HCV）和戊型肝炎（HEV）在疑似DILI患者中检测的重要性。最近的发现：几个国家DILI登记处报告了最初诊断为DILI的患者中的HCV和HEV感染。特别是在疑似DILI的急性肝细胞性肝损伤患者中，即使在没有传统危险因素的情况下，也应考虑急性HCV和急性HEV感染。对于HCV感染，建议检测HCV RNA和HCV抗体。对于HEV，HEV IgG抗体的高流行率意味着建议进行HEV IgM抗体检测以排除这种infection.SUMMARY-：在怀疑由DILI引起的急性肝细胞性肝损伤患者中，应高度怀疑急性HCV和HEV感染。
PURPOSE OF REVIEW-: Without a specific biomarker the diagnosis of drug-induced liver injury (DILI) relies on exclusion of other causes of liver injury. This review examines the importance of testing for hepatitis C (HCV) and hepatitis E (HEV) in patients with suspected DILI.RECENT FINDINGS-: Several national DILI registries have reported HCV and HEV infection in patients initially diagnosed with DILI. Particularly in patients with suspected DILI who have acute hepatocellular liver injury, acute HCV and acute HEV infection should be considered even in the absence of traditional risk factors. For HCV infection, testing for HCV RNA and HCV antibody are recommended. For HEV, the high prevalence of HEV IgG antibody means that HEV IgM antibody testing is suggested to exclude this infection.SUMMARY-: There should be a high clinical suspicion for acute HCV and HEV infection in patients with acute hepatocellular liver injury suspected of being due to DILI.